Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1199-1203

  Cheng, Ka Wing ^a   Mattheolabakis, George ^a   Wong, Chi C ^a   Ouyang, Nengtai ^a   Huang, Liqun ^a   Constantinides, Panayiotis P ^b   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

Hydrogel; Phospho sulindac; Skin cancer; Skin cancer treatment

Indexed keywords

ANTINEOPLASTIC AGENT; OXT 328; PHOSPHO SULINDAC; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; ORGANOPHOSPHORUS COMPOUNDS; SKIN NEOPLASMS; SULINDAC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866522062     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1577     Document Type: Article

References (23)

1. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E and Abeni D: Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 156 (Suppl 3): 1-7, 2007.
2. Kim RH and Armstrong AW: Nonmelanoma skin cancer. Dermatol Clin 30: 125-139, 2012.
3. Rogers HW, Weinstock MA, Harris AR, et al: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 146: 283-287, 2010.
4. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003.
5. Gravitz L: Chemoprevention: First line of defence. Nature 471: S5-S7, 2011.
6. Elmets CA, Viner JL, Pentland AP, et al: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102: 1835-1844, 2010.
7. Cuzick J, Otto F, Baron JA, et al: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507, 2009.
8. Nie T, Wong CC, Alston N, Aro P, Constantinides PP and Rigas B: Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo. Br J Pharmacol: Dec. 5, 2011 (Epub ahead of print).
9. Wong CC, Cheng KW, Xie G, et al: Carboxylesterases 1 and 2 hydrolyze phospho-NSAIDs: relevance to their pharmacological activity. J Pharmacol Exp Ther 340: 422-432, 2012.
10. Mattheolabakis G, Nie T, Constantinides PP and Rigas B: Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation. Pharm Res: Nov 10, 2011 (Epub ahead of print).
11. Huang L, Mackenzie GG, Sun Y, et al: Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res 71: 7617-7627, 2011.
12. Xie G, Nie T, Mackenzie G, et al: The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol 165: 2152-2166, 2012.
13. Sun Y, Huang L, Mackenzie GG and Rigas B: Oxidative stress mediates through apoptosis the anticancer effect of phosphononsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338: 775-783, 2011.
14. Mackenzie GG, Ouyang N, Xie G, et al: Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 4: 1052-1060, 2011.
15. Xie G, Sun Y, Nie T, et al: Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337: 876-886, 2011.
16. Huang L, Mackenzie G, Ouyang N, et al: The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol 162: 1521-1533, 2011.
17. Huang L, Zhu C, Sun Y, et al: Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis 31: 1982-1990, 2010.
18. Mackenzie GG, Sun Y, Huang L, et al: Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139: 1320-1332, 2010.
19. Kozoni V, Tsioulias G, Shiff S and Rigas B: The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis 21: 999-1005, 2000.
20. Ahmed S, Imai T, Yoshigae Y and Otagiri M: Stereospecific activity and nature of metabolizing esterases for propranolol prodrug in hairless mouse skin, liver and plasma. Life Sci 61: 1879-1887, 1997.
21. Akarsu S, Aktan S, Atahan A, Koc P and Ozkan S: Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. Clin Exp Dermatol 36: 479-484, 2011.
22. McCarberg BH and Argoff CE: Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. Int J Clin Pract 64: 1546-1553.
23. Fuller P and Roth S: Diclofenac sodium topical solution with dimethyl sulfoxide, a viable alternative to oral nonsteroidal anti-inflammatories in osteoarthritis: review of current evidence. J Multidiscip Healthc 4: 223-231, 2011.